(+)-JJ-74-138
(+)-JJ-74-138, a novel non-competitive androgen receptor (AR) antagonist, is capable of inhibiting Enzalutamide-resistant CRPC.
For research use only. We do not sell to patients.
- CAS No.: 2135545-34-3
- Formula: C22H22F8N2OS
- Molecular Weight:514.48
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
(+)-JJ-74-138 is a potent analog of JJ-450 for the inhibition of androgen-independent AR activation in cell lines expressing AR splice variants lacking the LBD[1].
(+)-JJ-74-138 inhibits mRNA expression of AR and ARv7 target genes and reduced AR level in the nucleus in the absence of androgens[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 2135545-34-3
-
Molecular Weight 514.48
-
Formula C22H22F8N2OS
-
SMILES
O=C(N1CCN(C2=CC(C(F)(F)F)=CC=C2C)CC1)[C@H]3[C@@H](C4=CC(S(F)(F)(F)(F)F)=CC=C4)C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
(+)-JJ-74-138 Related Classifications
HY-164371 Related Classifications
Powered by Bioz